The iPSC-Derived Cell Therapies Symposium – Recent Clinical Insights & Progress will take place on 12–13 November 2026 in Paris, France. Organised by CiTHERA and the Vaincre Le Cancer Foundation, the symposium will bring together leading scientists, clinicians, biotechnology companies, manufacturers, regulatory experts and other key stakeholders to discuss recent advances in iPSC-derived cell therapies and regenerative medicine.
The programme will address major scientific, translational, manufacturing and regulatory challenges in the development of iPSC-derived therapeutic products, with a particular focus on clinical progress, scalability, safety, quality control and patient-centred development pathways.
HAPLO-iPS is pleased to highlight the participation of our Action Chair, Dr Anna Veiga, who will present the HAPLO-iPS COST Action in Europe within the session European cGMP iPSC Landscape on the second day of the event. Her presentation will provide an important opportunity to showcase the objectives and progress of HAPLO-iPS in the broader European landscape of clinically relevant iPSC generation, banking, standardisation and future cell therapy applications.
Members of the HAPLO-iPS community and all colleagues interested in iPSC-derived therapies, regenerative medicine, GMP-compliant manufacturing and clinical translation are warmly encouraged to attend.
More information, agenda details and registration are available on the event website: https://www.b2match.com/e/ipsc-clinical-applications/components/69011/info